M Pharmaceutical, Inc. is changing the name of its wholly owned subsidiary M Pharmaceutical USA, to Callitas Therapeutics, Inc.

Callitas is a clinical-stage company developing products for weight management and female health and wellness. The new name is intended to reflect its broader commitment to drive innovations to shape the future of healthcare.

“Our new name, Callitas Therapeutics, reflects our wide-ranging business objective of developing and delivering innovative technologies for weight management and female health and wellness,” said Gary Thompson, president and chief executive officer of Callitas Therapeutics and M Pharma. “As a company with its roots in female health and wellness, we are committed to delivering breakthrough products and services that truly improve daily living. Aligning our logo with the beautiful and strong Calla Lily seems most appropriate in light of our mission.” 

Callitas was formed in early 2015. In addition to its recent acquisitions of C-103, a reformulation of Orlistat and assets from 40J’s LLC, M Pharma is scheduled to launch their FDA cleared fertility product branded as ToConceive  in September 2017.